Corticosteroid use in rheumatoid arthritis prevalence predictors correlates and outcomes

Results: Baseline corticosteroid use was comparable between groups (belimumab, 481 [%]; placebo, 241 [%]), with most patients receiving > mg/day (%). A numerically greater proportion of patients with baseline dose > mg/day in the belimumab group had a dose reduction of ≥25% to ≤ mg/day during Weeks 40–52 compared with patients receiving placebo (belimumab, %; placebo, %; OR [95% CI] [, ]; p=). Fewer patients in the belimumab group versus the placebo group required ≥50% increase (min ≥5 mg/day) in dose during Weeks 40–52 (Week 52: belimumab, %; placebo, %; OR [95% CI] [, ]; p=) or any increase in corticosteroid from Weeks 20–28 and 36–52 (Week 52: belimumab, %; placebo, %; OR [95% CI] [, ]; p=). The percentage of patients with ≥50% reduction in corticosteroid dose by Week 52 was similar in the belimumab (range: –%) and placebo (range: 0–%) groups. A small number of patients in each group required an increase (≥50%, min ≥5 mg/day) in dose from baseline (range: belimumab –%; placebo, –%). Mean (SD) cumulative corticosteroid dose at Week 52 was mg () in the belimumab group and mg () in the placebo group; the median (IQR) was the same in both groups ( [1825–5475]; p=). Median (IQR) corticosteroid dose at baseline was 10 mg/day (IQR 5–15) in both groups; no meaningful change occurred in either group by Week 52. Mean dose at baseline was mg/day and mg/day in the belimumab and placebo groups, with mean changes at Week 52 of - mg and - mg, respectively. Adverse events incidence (≥1) was similar (belimumab, %; placebo %).

Register for alerts
If you have registered for alerts, you should use your registered email address as your username

  • Citation tools Download this article to citation manager Crawshaw Dickon P , Helliwell Philip S , Hensor Elizabeth M A , Hay Elaine M , Aldous Simon J , Conaghan Philip G et al. Exercise therapy after corticosteroid injection for moderate to severe shoulder pain: large pragmatic randomised trial BMJ 2010; 340 :c3037
    • BibTeX (win & mac) Download
    • EndNote (tagged) Download
    • EndNote 8 (xml) Download
    • RefWorks Tagged (win & mac) Download
    • RIS (win only) Download
    • Medlars Download
    Help If you are unable to import citations, please contact technical support for your product directly (links go to external sites):

    Corticosteroid use in rheumatoid arthritis prevalence predictors correlates and outcomes

    corticosteroid use in rheumatoid arthritis prevalence predictors correlates and outcomes

    Media:

    corticosteroid use in rheumatoid arthritis prevalence predictors correlates and outcomescorticosteroid use in rheumatoid arthritis prevalence predictors correlates and outcomescorticosteroid use in rheumatoid arthritis prevalence predictors correlates and outcomescorticosteroid use in rheumatoid arthritis prevalence predictors correlates and outcomescorticosteroid use in rheumatoid arthritis prevalence predictors correlates and outcomes